Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Metabolism & Endocrine
Filter     Order     Display # 
Date Item Title Hits
01 Sep 2010 Biodel Announces Name Change for Lead Product Candidate 5
01 Sep 2010 Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC 4
30 Aug 2010 KYTHERA and Bayer Dermatology Unit Intendis Enter Licensing and Development Agreement for Adipolytic Agent ATX-101 6
26 Aug 2010 Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 6
24 Aug 2010 Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives 6
24 Aug 2010 PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 7
23 Aug 2010 Two-Year Data from Phase 2 Trial of Genzyme's Eliglustat Tartrate for Gaucher Disease To Be Published in the Journal Blood 5
19 Aug 2010 OXIS International, Inc. Announces Publication of Positive Results of Ergothioneine Safety Study in the Journal 'TOXICOLOGY' 10
18 Aug 2010 BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc. 28
17 Aug 2010 BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU 17
11 Aug 2010 KARO BIO TO PRESENT CLINICAL PHASE III DEVELOPMENT PLAN FOR EPROTIROME AS A NOVEL PHARMACEUTICAL FOR THE TREATMENT OF HEFH 22
10 Aug 2010 FDA Approves Innovative Liver Cell Therapy for Clinical Trial in the U.S. 10
10 Aug 2010 Amarin's AMR101 Pivotal Phase 3 MARINE Clinical Trial Completes Patient Enrollment and Randomization 14
06 Aug 2010 FDA Confirms September 16th Advisory Committee Meeting to Review Lorcaserin for Obesity and Weight Management 11
05 Aug 2010 Progress in Cancer Research: Characterisation of a New PPAR / Antagonist, GSK3787, with Roche's xCELLigence System 9
05 Aug 2010 Amicus Therapeutics Announces Continued Progress on Global Phase 3 Program for Fabry Disease and Second Quarter 2010 Financial Results 8
05 Aug 2010 Depomed Licenses GLUMETZA(R) Data and Acuform(R) Technology 11
04 Aug 2010 Data From Meta-Analysis Show Victoza(R) Achieved Improved Blood Sugar Control in African-Americans With Type 2 Diabetes 14
04 Aug 2010 Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen 25
03 Aug 2010 Encouraging Preliminary Safety and Efficacy Trends in Phase 2 Clinical Study of PEG-PAL in PKU 28
03 Aug 2010 Orexigen Therapeutics COR-BMOD Study Published in the Journal Obesity 29
02 Aug 2010 tudy Published in the Journal Endocrinology Further Confirms Therapeutic Potential of PROLOR's Long-Acting Human Growth Hormone 70
02 Aug 2010 Oxygen Biotherapeutics Signs CRADA With U.S. Navy to Study Treatment of Decompression Sickness Using Oxycyte(R) Emulsion 12
02 Aug 2010 Bionovo Announces Publication Describing Menerba's Effect on Neural Pathways Related to Temperature Regulation 28
02 Aug 2010 Osteologix and Servier Announce ex-US Licensing Agreement 10
29 Jul 2010 Abbott's SIMCOR (niacin extended-release / simvastatin) Receives FDA Approval for New Dosage Strengths 19
28 Jul 2010 Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH) 17
26 Jul 2010 Almirall signs a co-promotion agreement with Pfizer to commercialise Conbriza in Spain, a new therapeutic option to treat osteoporosis 20
23 Jul 2010 Emisphere Provides an Update on Osteoarthritis Phase III Study With Oral Calcitonin 23
22 Jul 2010 Pennington Biomedical Research Institute and Compellis Pharmaceuticals Complete Phase I Study of Novel and Patented Obesity Therapy 15
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1689

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease

Order Now

Recommended Report

R&D Drug Pipeline Database
Order Now

Subscribe La Merie Biologics